Incyte (INCY) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.

Do insiders and institutionals have more ownership in ALNY or INCY?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings & valuation, ALNY or INCY?

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.35B	16.58	-$278.16M	-$2.09	-142.86
Incyte	$4.41B	3.02	$32.62M	$0.32	215.16

Does the media prefer ALNY or INCY?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Incyte. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 13 mentions for Incyte. Incyte's average media sentiment score of 1.24 beat Alnylam Pharmaceuticals' score of 1.17 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, ALNY or INCY?

Alnylam Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Do analysts recommend ALNY or INCY?

Alnylam Pharmaceuticals presently has a consensus target price of $319.17, indicating a potential upside of 6.89%. Incyte has a consensus target price of $72.53, indicating a potential upside of 5.35%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77
Incyte	1 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.17

Does the MarketBeat Community favor ALNY or INCY?

Incyte received 61 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.32% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.15% of users gave Incyte an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1167 76.32%	Underperform Votes 362 23.68%
Incyte	Outperform Votes 1228 72.15%	Underperform Votes 474 27.85%

Is ALNY or INCY more profitable?

Incyte has a net margin of 0.77% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Incyte's return on equity of 0.05% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Incyte	0.77%	0.05%	0.04%

Summary

Incyte beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.